Company news
Immutep Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
March 29, 2023
Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
March 13, 2023
Enrolment Target Reached for INSIGHT-003 Trial in NSCLC
February 5, 2023
TACTI-003 trial 50% enrolment milestone has been achieved
January 3, 2023
Update on MBC trial design following successful FDA meeting
December 23, 2022
Commercial Scale in Manufacturing of Efti Achieved
December 7, 2022
GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist
December 5, 2022
Immutep enters 2nd collaboration with Pfizer and Merck KGaA
November 28, 2022
Immutep receives A$1 million R&D Tax Incentive
November 13, 2022
Immutep Webcast to discuss clinical data presented at SITC
November 10, 2022
New Patents Granted in Japan and South Korea for Efti
November 9, 2022
Late Breaking Abstract accepted for SITC Oral Presentation
November 2, 2022
Independent DMC recommends to continue TACTI-003 as planned
October 25, 2022
Abstracts accepted for Presentation at SITC 2022
October 5, 2022
Fast Track granted by US FDA for Efti in 1st line NSCLC
October 3, 2022
Immutep Receives A$2.7 million R&D French Tax Incentive
September 22, 2022
Clinical Development Update for Eftilagimod Alpha
September 13, 2022
New investigator-initiated ph2 trial in Soft Tissue Sarcoma
September 5, 2022
Appendix 4E & 2022 Full Year Statutory Accounts
August 31, 2022
Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
August 30, 2022
TACTI-002 2nd line lung cancer data presented at 2022 WCLC
July 31, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
July 28, 2022
Immutep granted Japanese Patent for IMP761
July 5, 2022
Webcast slides for 1st line NSCLC data from TACTI-002 trial
June 5, 2022
Immutep announces publication of ASCO 2022 abstracts
May 26, 2022
New & significant data from AIPAC phase 2b trial in MBC
May 4, 2022
Immutep to announce new TACTI-002 data at ASCO 2022
April 27, 2022
Efti with Keytruda shows encouraging activity in lung cancer
March 29, 2022
Immutep announces publication of ELCC 2022 abstract
March 23, 2022
Japanese patent granted for LAG-3 antibody LAG525
March 18, 2022
Immutep receives FDA feedback for Efti development in MBC
March 9, 2022
Australian Patent Granted for Efti with PD-1 Inhibitors
February 11, 2022
Immutep Advances IMP761 Manufacturing
December 15, 2021
Good safety reported from 1st five patients in INSIGHT-003
December 1, 2021
Phase II TACTI-002 trial recruitment successfully completed
November 18, 2021
Immutep Global Webcast Slides to Discuss Clinical Results
November 16, 2021
Immutep announces publication of SITC 2021 posters
November 14, 2021
Immutep announces publication of SITC 2021 abstracts
November 9, 2021
Immutep granted Chinese Patent for eftilagimod alpha
November 2, 2021
Immutep receives EMA scientific advice for Phase 3 in MBC
October 28, 2021
Immutep Quarterly Activities Report & Appendix 4C
October 27, 2021
Immutep Receives A$3.4 million R&D French Tax Incentive
September 28, 2021
Recruitment of patients completed for Part B of TACTI-002
September 1, 2021
Immuteps partner, EOC Pharma, expands efti trial pipeline
August 30, 2021
Chinese patent granted for anti-LAG-3 antibody LAG525
August 26, 2021
INSIGHT-003 investigator-initiated trial - 1st patient dosed
August 4, 2021
Completion of Placement - Tranche 2
July 29, 2021
Completion of Share Purchase Plan
July 20, 2021
US FDA & IRB approves start of ph2b head & neck cancer trial
July 5, 2021
Efti to be evaluated in new triple combination therapy trial
June 21, 2021
Decks
The 5 newest of 112 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 30 slides · Aug 20, 2026
- Investor Presentation (February 2026)
Investor deck · 39 slides · Feb 20, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 27, 2025
- Investor Presentation (October 2025)
Investor deck · 37 slides · October 2025
- Jefferies Global Healthcare Conference 2025
Conference · 40 slides · Jun 2, 2025